CN103816182B - 一种血液滤过置换液及其制备方法 - Google Patents
一种血液滤过置换液及其制备方法 Download PDFInfo
- Publication number
- CN103816182B CN103816182B CN201410066806.0A CN201410066806A CN103816182B CN 103816182 B CN103816182 B CN 103816182B CN 201410066806 A CN201410066806 A CN 201410066806A CN 103816182 B CN103816182 B CN 103816182B
- Authority
- CN
- China
- Prior art keywords
- ion
- sodium
- group
- hemofiltration replacement
- hemofiltration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002615 hemofiltration Methods 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000012530 fluid Substances 0.000 title abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 11
- -1 citrate ions Chemical class 0.000 claims abstract description 11
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229910001868 water Inorganic materials 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 53
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 45
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 239000008215 water for injection Substances 0.000 claims description 12
- 235000008151 pyridoxamine Nutrition 0.000 claims description 11
- 239000011699 pyridoxamine Substances 0.000 claims description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 10
- 229930003268 Vitamin C Natural products 0.000 claims description 10
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 10
- 229960000304 folic acid Drugs 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 239000011781 sodium selenite Substances 0.000 claims description 10
- 229960001471 sodium selenite Drugs 0.000 claims description 10
- 235000015921 sodium selenite Nutrition 0.000 claims description 10
- 235000019154 vitamin C Nutrition 0.000 claims description 10
- 239000011718 vitamin C Substances 0.000 claims description 10
- 241000370738 Chlorion Species 0.000 claims description 8
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 8
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 8
- 229910001415 sodium ion Inorganic materials 0.000 claims description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 7
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229910001414 potassium ion Inorganic materials 0.000 claims description 6
- 230000036571 hydration Effects 0.000 claims description 5
- 238000006703 hydration reaction Methods 0.000 claims description 5
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 5
- 230000003204 osmotic effect Effects 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000003610 charcoal Substances 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 16
- 239000011574 phosphorus Substances 0.000 abstract description 16
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 11
- 239000011734 sodium Substances 0.000 abstract description 11
- 229910052708 sodium Inorganic materials 0.000 abstract description 11
- 208000029663 Hypophosphatemia Diseases 0.000 abstract description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000460 chlorine Substances 0.000 abstract description 5
- 229910052801 chlorine Inorganic materials 0.000 abstract description 5
- 239000011591 potassium Substances 0.000 abstract description 5
- 229910052700 potassium Inorganic materials 0.000 abstract description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 4
- 239000011777 magnesium Substances 0.000 abstract description 4
- 229910052749 magnesium Inorganic materials 0.000 abstract description 4
- 239000011573 trace mineral Substances 0.000 abstract description 3
- 235000013619 trace mineral Nutrition 0.000 abstract description 3
- 230000010100 anticoagulation Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 28
- 238000006073 displacement reaction Methods 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 229910052791 calcium Inorganic materials 0.000 description 12
- 238000011973 continuous veno-venous hemofiltration Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 229910052711 selenium Inorganic materials 0.000 description 6
- 229940091258 selenium supplement Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000009256 replacement therapy Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- PLZNPHDJGFDNRM-UHFFFAOYSA-M O.[Na+].[O-][PH2]=O Chemical compound O.[Na+].[O-][PH2]=O PLZNPHDJGFDNRM-UHFFFAOYSA-M 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010027423 Metabolic alkalosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010050702 Crush syndrome Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GSOLWAFGMNOBSY-UHFFFAOYSA-N cobalt Chemical compound [Co][Co][Co][Co][Co][Co][Co][Co] GSOLWAFGMNOBSY-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
钠离子(mmol/L) | 130 |
镁离子(mmol/L) | 0.75 |
钾离子(mmol/L) | 0 |
钙离子(mmol/L) | 1.4 |
氯离子(mmol/L) | 100 |
磷酸二氢根离子(mmol/L) | 1.0 |
枸橼酸根离子(mmol/L) | 12 |
维生素C(μmol/L) | 100 |
叶酸(nmol/L) | 40 |
维生素B6(nmol/L) | 100 |
***钠(nmol/l) | 1000 |
葡萄糖(mmol/L) | 8 |
渗透压(mOsm/kg) | 280-285 |
钠离子(mmol/L) | 125 |
镁离子(mmol/L) | 0.75 |
钙离子(mmol/L) | 1.0 |
钾离子(mmol/L) | 2 |
氯离子(mmol/L) | 92.75 |
磷酸二氢根离子(mmol/L) | 0.5 |
枸橼酸根离子(mmol/L) | 16 |
葡萄糖(mmol/L) | 5 |
***钠(nmol/l) | 1000 |
渗透压(mOsm/kg) | 280-285 |
钠离子(mmol/L) | 145 |
镁离子(mmol/L) | 0.5 |
钾离子(mmol/L) | 2.5 |
钙离子(mmol/L) | 1.7 |
氯离子(mmol/L) | 110 |
磷酸二氢根离子(mmol/L) | 1.5 |
枸橼酸根离子(mmol/L) | 8 |
维生素C(μmol/L) | 150 |
叶酸(nmol/L) | 80 |
维生素B6(nmol/L) | 80 |
葡萄糖(mmol/L) | 12 |
渗透压(mOsm/kg) | 280-285 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410066806.0A CN103816182B (zh) | 2014-02-26 | 2014-02-26 | 一种血液滤过置换液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410066806.0A CN103816182B (zh) | 2014-02-26 | 2014-02-26 | 一种血液滤过置换液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103816182A CN103816182A (zh) | 2014-05-28 |
CN103816182B true CN103816182B (zh) | 2016-05-25 |
Family
ID=50751665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410066806.0A Active CN103816182B (zh) | 2014-02-26 | 2014-02-26 | 一种血液滤过置换液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103816182B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622894A (zh) * | 2014-12-19 | 2015-05-20 | 周飞虎 | 一种血液净化置换液 |
CN105687231A (zh) * | 2016-03-11 | 2016-06-22 | 南京大学医学院附属鼓楼医院 | 一种新的血液滤过用复方枸橼酸钠注射液配方 |
CN107281098A (zh) * | 2017-06-30 | 2017-10-24 | 华仁药业股份有限公司 | 一种血液滤过置换液 |
CN107890568A (zh) * | 2017-10-31 | 2018-04-10 | 华仁药业股份有限公司 | 一种低危害的血液滤过置换液及其制备工艺 |
CN108685942A (zh) * | 2018-04-23 | 2018-10-23 | 杨荣利 | 一种用于枸橼酸盐抗凝的无钙置换液/透析液 |
CN109200366A (zh) * | 2018-11-09 | 2019-01-15 | 南通大学附属医院 | 连续性血液净化治疗置换液专用配液车 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863539A (zh) * | 2003-06-24 | 2006-11-15 | 高级肾脏技术公司 | 透析用缓冲的组合物 |
CN101861153A (zh) * | 2007-08-15 | 2010-10-13 | 康利隆日本公司 | 腹膜透析液 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8133194B2 (en) * | 2006-02-22 | 2012-03-13 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
-
2014
- 2014-02-26 CN CN201410066806.0A patent/CN103816182B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863539A (zh) * | 2003-06-24 | 2006-11-15 | 高级肾脏技术公司 | 透析用缓冲的组合物 |
CN101861153A (zh) * | 2007-08-15 | 2010-10-13 | 康利隆日本公司 | 腹膜透析液 |
Also Published As
Publication number | Publication date |
---|---|
CN103816182A (zh) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103816182B (zh) | 一种血液滤过置换液及其制备方法 | |
MXPA06000973A (es) | Soluciones de dialisis con niveles reducidos de productos de degradacion de glucosa. | |
Chase et al. | Plasma amino acid profiles in patients with fulminant hepatic failure treated by repeated polyacrylonitrile membrane hemodialysis | |
CN101991589A (zh) | 一种甘油果糖注射液及其制备方法 | |
CN104622896A (zh) | 一种钠钾镁钙葡萄糖注射液的制备方法 | |
CN103393715B (zh) | 钠钾镁钙葡萄糖注射液及其制备方法 | |
CN107550928A (zh) | 一种葡萄糖聚合物腹膜透析液及其制备工艺 | |
CN103385889A (zh) | 混合糖电解质注射液及其制备方法 | |
JP6425661B2 (ja) | 透析組成物 | |
CN101439047B (zh) | 提高人凝血酶原复合物稳定性fvii得率的工艺方法 | |
CN105287369A (zh) | 一种防止塑瓶装氯化钠注射液药液浑浊的生产方法 | |
CN105168128A (zh) | 防止塑瓶装氯化钠注射液瓶体变黄且药液浑浊的生产方法 | |
CN104622894A (zh) | 一种血液净化置换液 | |
CN1857311A (zh) | 用于血液净化治疗的血液置换基础液 | |
CN109078019B (zh) | 一种双室袋包装的碳酸氢盐透析液及其制备方法 | |
CN103432638B (zh) | 一种血液透析浓缩液的生产设备及其血液透析浓缩液的生产方法 | |
CN115811988A (zh) | 一种血液净化分子浓缩物及其制备方法与应用 | |
CN103638526B (zh) | 一种血液净化用制剂及其制备方法与应用 | |
CN102240261A (zh) | 一种葡甘露聚糖注射液的制备方法及其医学用途 | |
Shockley et al. | New solutions for peritoneal dialysis in adult and pediatric patients | |
CN101721424B (zh) | 碳酸氢盐生理平衡液及其制备方法 | |
CN101485453B (zh) | 一种保持植物铁蛋白稳定的方法 | |
Gouyon et al. | Urea removal by hemofiltration and hemodiafiltration | |
CN108685942A (zh) | 一种用于枸橼酸盐抗凝的无钙置换液/透析液 | |
CN112294839A (zh) | 一种预防和降低腹膜纤维化的腹膜透析液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171024 Address after: 14 No. 610041 Sichuan province Chengdu high tech Zone Gaopeng Avenue Patentee after: CHENGDU QINGSHAN LIKANG PHARMACEUTICAL Co.,Ltd. Address before: 610041 Wuhou District, Chengdu, China, No. Guoxue lane, No. 37 Patentee before: WEST CHINA HOSPITAL OF SICHUAN University |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: No.14 Gaopeng Avenue, high tech Zone, Chengdu, Sichuan 610000 Patentee after: Chengdu Qingshan Likang Pharmaceutical Co.,Ltd. Address before: No. 14 Gaopeng Avenue, Chengdu High tech Zone, Sichuan Province, 610041 Patentee before: CHENGDU QINGSHAN LIKANG PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |